

[View related articles](#)



View Crossmark data [↗](#)

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study

Tim A. C. de Vries^{a,b} , Martin E. W. Hemels^{a,c} , Frank Cools^d , Harry J. G. M. Crijns^e , Laetitia Yperzeele^f , Peter Vanacker^{f,g} , Ivan Blankoff^h , Patrizio Lancellottiⁱ , Georges H. Mairesse^j , Anne de Veer^k , Ruben Casado Arroyo^l , Emmanuel Catez^m , Michel de Pauwⁿ , Thomas Vanassche^o , Carlo de Asmundis^p , Paulus Kirchhof^{q,r} , Raffaele De Caterina^s , Joris R. de Groot^b  On behalf of the ETNA-AF-Europe principal investigators from Belgium and the Netherlands*

^aDepartment of Cardiology, Rijnstate Hospital, Arnhem, The Netherlands; ^bDepartment of Cardiology, Amsterdam Medical Centres/ University of Amsterdam, Amsterdam, The Netherlands; ^cDepartment of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands; ^dDepartment of Cardiology, General Hospital Klinieken Noord-Antwerpen, Brasschaat, Belgium; ^eDepartment of Cardiology, Maastricht University Medical Centre, Maastricht, The Netherlands; ^fDepartment of Neurosurgery, University Hospital Antwerp, Antwerp, Belgium; ^gDepartment of Neurology, General Hospital Groeninge, Kortrijk, Belgium; ^hDepartment of Cardiology, Civil Hospital Marie Curie, Charleroi, Belgium; ⁱDepartment of Cardiology, University Hospital of Liège, Liège, Belgium; ^jDepartment of Cardiology, Cliniques du Sud-Luxembourg, Arlon, Belgium; ^kDepartment of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; ^lDepartment of Cardiology, Hospital Erasme, Anderlecht, Belgium; ^mDepartment of Cardiology, Brugmann University Hospital, Brussels, Belgium; ⁿDepartment of Cardiology, Ghent University Hospital, Ghent, Belgium; ^oDepartment of Cardiology, Leuven University Hospital, Leuven, Belgium; ^pDepartment of Cardiology, University Hospital Brussels, Brussels, Belgium; ^qInstitute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK; ^rThe Atrial Fibrillation NETwork (AFNET), Münster, Germany; ^sDepartment of Cardiology, University of Pisa, Pisa, Italy

ABSTRACT

Background: Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.

Methods: With data from Edoxaban Treatment in routine clinical practice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15–50 mL/min, weight ≤60 kg, and/or use of strong p-glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC).

Results: Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA₂DS₂-VAsC (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.

Conclusion: There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.

Trial registration: NCT02944019; Date of registration: October 24, 2016.

ARTICLE HISTORY

Received 31 January 2020;
Revised 17 March 2020; Accepted 18 March 2020

KEYWORDS

anticoagulants; haemorrhage; off-label use; clinical trial, phase IV; stroke; thromboembolism

Introduction

Several large real-world evidence studies have been performed to study the safety of the non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in unselected patients with atrial fibrillation

CONTACT Tim A. C. de Vries  t.a.devries@amsterdamumc.nl  Amsterdam Medical Centres, University of Amsterdam, Meibergdreef 9, Amsterdam 1105, AZ, The Netherlands

*See supplemental data for the principal investigators of ETNA-AF-Europe from Belgium and the Netherlands

 Supplemental data for this article can be accessed [here](https://doi.org/10.1007/s12471-020-01518-7).

This article has been published in two journals by kind permissions of the editors and publishers. The text of the article is the same in both publications. This article is also available at <https://doi.org/10.1007/s12471-020-01518-7>

© The Author(s) 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

(AF). These studies confirm that the use of NOACs in routine clinical practice is safe and efficacious, but also show that their reduced doses are far more often prescribed than in the randomised controlled trials (RCTs) [1–14]. These and other phase IV studies on the use of NOACs in patients with AF show important differences among geographical regions regarding patient characteristics and prescription patterns [1,5–10,12–14].

Such information is crucial to allow healthcare personnel (e.g. physicians, pharmacologists, or policymakers) to more accurately address potential local issues, as well as to translate findings of continental or global studies to our local practices. However, as all these studies included data before or shortly after the approval of edoxaban, such data on this NOAC are scarce [1,5–10,12–15].

Edoxaban is a direct factor Xa inhibitor, approved in 2015 for stroke prevention in adult non-valvular AF patients [15]. According to its Summary of Product Characteristics (SmPC), the approved dose is 60 mg once daily (OD), with a dose reduction to 30 mg OD in patients with a creatinine clearance (CrCl) between 15 and 50 mL/min, a body weight ≤ 60 kg, and/or concomitant use of strong p-glycoprotein (p-gp) inhibitors, i.e. cyclosporine, dronedarone, erythromycin, and ketoconazole [15].

Recently, the Edoxaban Treatment in routiNe clinical prActice for patients with non-valvular AF in Europe (ETNA-AF Europe) study (Clinicaltrials.gov: NCT02944019) completed patient enrolment. This registry allows us to determine whether there are also important regional differences in clinical practice for edoxaban [16]. Here, we describe the characteristics of edoxaban users with AF from Belgium and the Netherlands (BeNe) compared to those from other European countries (OEC).

Methods

The ETNA-AF-Europe registry study is an observational post-authorisation study in which patients from ten European countries (Austria, Belgium, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Switzerland, and the United Kingdom) are followed for up to 48 months. All patients with AF, diagnosed by electrical tracing (i.e. electrocardiogram, Holter monitoring, pacemaker or a different implantable device) within the last 12 months, and treated with edoxaban were eligible for inclusion. No explicit exclusion criteria were applied [17].

In addition to standard demographics, data on the history of cardiovascular diseases (e.g. hypertension, prior ischaemic stroke or major bleeding), weight, renal

function, and on AF-related therapies (e.g. prior use of anticoagulants, and current use of antiplatelet drugs) were collected. Other details on the methods and design of ETNA-AF-Europe have been reported previously [17].

Although ETNA-AF-Europe is one of the largest phase IV registries on patients with AF to date, we decided that due to modest patient numbers per country, pooling data from two neighbouring countries would be more desirable than to further divide regions with the result of precluding meaningful comparisons.

Based on the above considerations, we extracted data on the baseline characteristics of patients from BeNe that were enrolled in ETNA-AF-Europe; determined the proportional use of 30 mg OD and 60 mg OD edoxaban, and whether dose selection was in accordance with the SmPC (except for concomitant use of p-gp inhibitors). We then compared these findings with those from OEC to assess for clinically important regional differences.

In line with our rationale to interpret findings from continental or global studies in a regional context, we also compared characteristics of patients observed in ETNA-AF-Europe that were from BeNe with those from the corresponding countries once enrolled in the Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation – Thrombolysis in Myocardial Infarction 48 (ENGAGE-AF-TIMI 48) trial [3].

Results

Belgium and The Netherlands compared with other European countries

A total of 13,639 (97.6% of the 13,980 enrolled patients in ETNA-AF-Europe) were included in our analyses. Of these, 2579 (18.9%) were from the BeNe: 1316 (9.6%) from Belgium, and 1263 (9.3%) from the Netherlands (Figure 1). The baseline demographics and clinical characteristics for patients enrolled throughout all OEC, and those in BeNe, stratified by dose of edoxaban, are summarised in Table 1.

Overall, 86.4% and 82.4% of patients in BeNe and OEC, respectively, were treated with edoxaban at doses conforming to the SmPC. Relatively fewer patients in BeNe compared to OEC were treated with the reduced dose of edoxaban (14.8% vs 25.4%), but the distribution of 30 mg prescriptions in the absence of any dose reduction criteria was similar between both regions: 36.9% of 30 mg users (5.5% of all patients) in BeNe, compared with 35.5% (9.0% of all patients) in OEC (Figure 2).

Mean CHA₂DS₂-VAsC scores were 2.6 for 60 mg users and 3.6 for 30 mg users in BeNe, compared with




Figure 1. Patient selection.

Overview of patient enrolment in the ETNA-AF-Europe registry. ETNA-AF Europe: Edoxaban Treatment in routiNe clinical prActice for patients with non-valvular Atrial Fibrillation in Europe, OD once daily. ^aAustria, Germany, Ireland, Italy, Portugal, Spain, Switzerland, and the United Kingdom.

3.0 and 3.8, respectively, in OEC. Mean HAS-BLED scores were 2.3 for patients on standard dose edoxaban and 2.9 for those on the reduced dose in BeNe, compared with 2.5 and 3.0, respectively, in OEC (Figure 3). Overall, in patients from BeNe, a history with cardiovascular disease was less prevalent than in OEC, in particular hypertension (61.6% vs 80.4%) and diabetes mellitus (17.3% vs 23.1%). In contrast, prior ischaemic events were more often reported in BeNe compared with in OEC.

Physicians from BeNe less often described their patients as frail compared with those from OEC (5.9% vs 11.7%). This trend was prevalent in both dosing groups: in BeNe 19.1% of patients on 30 mg were considered frail, and 3.6% of those on 60 mg, compared with 26.1% and 6.8%, respectively, in OEC.

The current type of AF also differed among both regions, which was most marked for the 30 mg group. Thus, for BeNe patients prescribed 30 mg of edoxaban, 65.7% had paroxysmal AF, and 11.3% permanent, compared with 48.1%, and 27.7%, respectively, of patients prescribed 30 mg in the OEC. For the patients on 60 mg from BeNe, paroxysmal was reported in 64.7% of cases and permanent in 11.2%, relative to 51.8% and 19.5%, respectively, in the other regions of Europe.

Belgium and The Netherlands: clinical practice versus the phase III trial

The baseline characteristics of patients from BeNe enrolled in the ETNA-AF-Europe registry and those from the corresponding countries included in the ENGAGE-AF-TIMI 48 trial are summarised in Table 2.

Overall, 302 patients from BeNe were enrolled in the RCT (vs 2579 in the registry). CHA₂DS₂-VASc scores were much lower in the registry than in the RCT (mean: 2.8 vs 4.2), as were the rates of prior cardiovascular diseases. Conversely, HAS-BLED scores were higher in ETNA-AF-Europe than in ENGAGE-AF-TIMI 48 (mean: 2.4 vs 1.6).

Discussion

Our analyses on differences among geographical regions regarding patient characteristics and prescription patterns using baseline data from ETNA-AF-Europe show three important observations. First, the 30 mg dose of edoxaban was used much more frequently in OEC than in BeNe. Second, compared with those from OEC patients from BeNe had slightly better overall prognostic characteristics. Lastly, patients from BeNe once enrolled in ENGAGE-AF-TIMI 48 generally had characteristics that put them at much higher baseline risks of stroke than those from our cohort.

Less use of 30 mg edoxaban and better prognostic characteristics in Belgium and The Netherlands compared with in other European countries

Our results show that the 30 mg dose was used far less frequently in BeNe than in the OEC. However, rates of use of the 30 mg dose in the absence of any dose reduction criteria were similar among both regions, which can only be explained by relatively fewer patients in BeNe than in OEC with criteria for dose reduction: 14.5% in BeNe had a CrCl $\leq$ 50 mL/min compared with 22.4% in OEC; and 8.9% and 10.7% had a body weight $\leq$ 60 kg in BeNe and OEC,

Table 1. Patient characteristics.

Characteristics	Belgium and the Netherlands			Other European countries		
	Overall (n = 2579)	60 mg OD (n = 2197)	30 mg OD (n = 382)	Overall (n = 11,060)	60 mg OD (n = 8248)	30 mg OD (n = 2812)
30 mg users	382 (14.8)	0 (0.0)	382 (100.0)	2812 (25.4)	0 (0.0)	2812 (100.0)
Male	1514 (58.8)	1356 (61.8)	158 (41.4)	6193 (56.0)	4961 (60.1)	1232 (43.8)
Age (years)	72.3 ± 9.1	71.2 ± 8.7	78.9 ± 8.4	73.9 ± 9.6	71.9 ± 9.3	79.7 ± 7.8
Age subgroups (years)						
<65	439 (17.0)	422 (19.2)	17 (4.5)	1658 (15.0)	1541 (18.7)	117 (4.2)
65–74	1056 (41.0)	969 (44.1)	87 (22.8)	3550 (32.1)	3062 (37.1)	488 (17.4)
75–84	882 (34.2)	704 (32.1)	178 (46.6)	4618 (41.8)	3191 (38.7)	1427 (50.8)
≥85	200 (7.8)	100 (4.6)	100 (26.2)	1232 (11.1)	453 (5.5)	779 (27.7)
Weight (kg)	82.3 ± 17.4	84.1 ± 16.9	72.3 ± 17.2	80.7 ± 17.3	83.4 ± 16.7	72.9 ± 16.6
BMI (kg/m ²)	28.0 ± 5.1	28.3 ± 5.0	26.1 ± 4.9	28.1 ± 5.2	28.7 ± 5.1	26.6 ± 5.1
Blood pressure (mmHg)						
Systolic	136.3 ± 20.3	135.9 ± 20.2	138.1 ± 21.0	132.8 ± 17.4	133.1 ± 17.1	131.9 ± 18.0
Diastolic	78.8 ± 12.4	79.3 ± 12.3	76.0 ± 12.1	78.2 ± 10.5	78.9 ± 10.5	76.2 ± 10.4
Active smokers	208 (8.1)	184 (8.4)	24 (6.3)	651 (5.9)	535 (6.5)	116 (4.1)
No alcohol use	629 (24.4)	501 (22.8)	128 (33.5)	5483 (49.7)	3880 (47.1)	1603 (57.0)
CrCl ^a (mL/min)	78.4 ± 29.7	83.7 ± 28.2	49.6 ± 19.3	73.5 ± 30.6	81.9 ± 29.5	50.3 ± 19.8
CrCl ^a subgroups (mL/min)						
<15	0 (0.0)	0 (0.0)	0 (0.0)	2 (0.0)	0 (0.0)	2 (0.1)
15–30	45 (2.0)	9 (0.5)	36 (10.5)	250 (2.6)	30 (0.4)	220 (8.7)
30–50	276 (12.5)	113 (6.0)	163 (47.5)	1899 (19.8)	585 (8.3)	1314 (51.7)
50–80	953 (43.0)	830 (44.4)	123 (35.9)	4095 (42.7)	3286 (46.6)	809 (31.8)
≥80	940 (42.5)	919 (49.1)	21 (6.1)	3349 (34.9)	3152 (44.7)	197 (7.7)
Renal disease	360 (14.0)	206 (9.4)	154 (40.3)	3329 (30.1)	1836 (22.3)	1493 (53.1)
CHADS ₂ ^a	1.5 ± 1.1	1.4 ± 1.1	2.0 ± 1.1	1.8 ± 1.1	1.7 ± 1.0	2.2 ± 1.0
CHA ₂ DS ₂ -VASC ^a	2.8 ± 1.4	2.6 ± 1.4	3.6 ± 1.3	3.2 ± 1.4	3.0 ± 1.4	3.8 ± 1.3
Score of 0	99 (3.8)	97 (4.4)	2 (0.5)	211 (1.9)	203 (2.5)	8 (0.3)
Score of ≥1	2480 (96.2)	2100 (95.6)	380 (99.5)	10,849 (98.1)	8045 (97.5)	2804 (99.7)
HAS-BLED ^a	2.4 ± 1.2	2.3 ± 1.1	2.9 ± 1.2	2.6 ± 1.1	2.5 ± 1.1	3.0 ± 1.1
Frailty ^b						
Yes	153 (5.9)	80 (3.6)	73 (19.1)	1289 (11.7)	556 (6.8)	733 (26.1)
No	2184 (84.7)	1915 (87.2)	269 (70.4)	9076 (82.2)	7192 (87.4)	1884 (67.0)
Unknown	240 (9.3)	200 (9.1)	40 (10.5)	677 (6.1)	482 (5.9)	195 (6.9)
History of cardiovascular diseases						
Hypertension	1589 (61.6)	1335 (60.8)	254 (66.5)	8891 (80.4)	6588 (79.9)	2303 (81.9)
CHF	109 (4.2)	73 (3.3)	36 (9.4)	690 (6.2)	422 (5.1)	268 (9.5)
MI	130 (5.0)	94 (4.3)	36 (9.4)	454 (4.1)	293 (3.6)	161 (5.7)
Angina pectoris	47 (1.8)	37 (1.7)	10 (2.6)	154 (1.4)	97 (1.2)	57 (2.0)
Valvular disease	345 (13.4)	252 (11.5)	93 (24.3)	2081 (18.8)	1445 (17.5)	636 (22.6)
PAD	93 (3.6)	79 (3.6)	14 (3.7)	365 (3.3)	214 (2.6)	151 (5.4)
DM	445 (17.3)	360 (16.4)	85 (22.3)	2551 (23.1)	1782 (21.6)	769 (27.3)
History of stroke						
Ischaemic	154 (6.0)	121 (5.5)	33 (8.6)	662 (6.0)	472 (5.7)	190 (6.8)
Cryptogenic	10 (0.4)	9 (0.4)	1 (0.3)	71 (0.6)	44 (0.5)	27 (1.0)
TIA	129 (5.0)	105 (4.8)	24 (6.3)	334 (3.0)	238 (2.9)	96 (3.4)
History of bleeding						
Gastrointestinal ^c	19 (0.7)	14 (0.6)	5 (1.3)	89 (0.8)	39 (0.5)	50 (1.8)
Major	31 (1.2)	24 (1.1)	7 (1.8)	102 (0.9)	58 (0.7)	44 (1.6)
Intracranial	19 (0.7)	16 (0.7)	3 (0.8)	48 (0.4)	30 (0.4)	18 (0.6)
Atrial fibrillation type						
Paroxysmal	1668 (64.9)	1417 (64.7)	251 (65.7)	5612 (50.9)	4261 (51.9)	1351 (48.1)
Persistent	585 (22.8)	500 (22.8)	85 (22.3)	2724 (24.7)	2131 (25.9)	593 (21.1)
Long-standing persistent	30 (1.2)	27 (1.2)	3 (0.8)	303 (2.7)	217 (2.6)	86 (3.1)
Permanent	228 (11.2)	245 (11.2)	43 (11.3)	2382 (21.6)	1606 (19.5)	776 (27.7)
Burden of atrial fibrillation						
Symptomatic	1479 (57.4)	1285 (58.6)	194 (50.8)	5776 (52.3)	4404 (53.5)	1372 (48.8)
Asymptomatic	856 (33.2)	714 (32.5)	142 (37.2)	3762 (34.1)	2758 (33.5)	1004 (35.7)
Unknown	241 (9.4)	195 (8.9)	46 (12.0)	1500 (13.6)	1066 (13.0)	434 (15.4)
Time since the diagnosis of atrial fibrillation – months						
Median (IQR)	1.9 (0.3; 27.5)	1.9 (0.3; 28.1)	2.0 (0.2; 20.1)	5.5 (0.5; 29.7)	4.8 (0.4; 26.3)	7.5 (0.8; 39.1)
Previous (not current) use of atrial fibrillation relevant medication						
VKA	540 (20.9)	469 (21.3)	71 (18.6)	1781 (16.1)	1238 (15.0)	543 (19.3)
NOAC (other)	174 (6.7)	136 (6.2)	38 (9.9)	924 (8.4)	588 (7.1)	336 (11.9)
Rate or rhythm	238 (9.2)	201 (9.1)	37 (9.7)	445 (4.0)	327 (4.0)	118 (4.2)
Antiplatelets	498 (19.3)	414 (18.8)	84 (22.0)	1572 (14.2)	1137 (13.8)	435 (15.5)
Number of dose adjustment criteria ^d						
0	2127 (82.5)	1986 (90.4)	141 (36.9)	8293 (75.0)	7295 (88.4)	998 (35.5)
≥1	452 (17.5)	211 (9.6)	241 (63.1)	2767 (25.0)	953 (11.6)	1814 (64.5)

(continued)

Table 1. Continued.

Characteristics	Belgium and the Netherlands			Other European countries		
	Overall (n = 2579)	60 mg OD (n = 2197)	30 mg OD (n = 382)	Overall (n = 11,060)	60 mg OD (n = 8248)	30 mg OD (n = 2812)
Dose adjustment criteria ^d						
CrCl ^a ≤ 50 mL/min	321 (14.5)	122 (6.5)	199 (58.0)	2151 (22.4)	615 (8.7)	1536 (60.4)
Weight ≤ 60 kg	211 (8.9)	98 (4.8)	113 (31.7)	1158 (10.7)	409 (5.1)	749 (27.2)

This table summarises the clinical characteristics of patients from Belgium or the Netherlands that were enrolled in ETNA-AF-Europe, and of those from the other European countries participating in the registry. Values are in number (%), or mean ± SD unless stated otherwise.

OD: once daily; SD: standard deviation; BMI: body mass index; mmHg: millimetre of mercury; CrCl: creatinine clearance; CHADS₂: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke (double weight); CHA₂DS₂-VASc: congestive heart failure, hypertension, age ≥ 75 years (double weight), diabetes mellitus, stroke (double weight), vascular disease, age 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile International Normalised Ratio, elderly, drugs or alcohol; NR: not reported; CHF: chronic heart failure; MI: myocardial infarction; PAD: peripheral artery disease; DM: diabetes mellitus; TIA: transient ischaemic attack; IQR: interquartile range; VKA: vitamin K antagonist; NOAC: non-vitamin K antagonist oral anticoagulant; ETNA-AF-Europe: Edoxaban Treatment in routine clinical practice for patients with non-valvular Atrial Fibrillation in Europe.

^aSome parameters were reported by the investigators as well as recalculated based on data reported by the investigators. Presented values are those that were recalculated.

^bThere was no specific definition for frailty; it was left to the discretion of the physician to categorise a patient as frail.

^cComposite of major bleeding and clinically relevant non-major bleeding.

^dNot including concomitant use of p-glycoprotein inhibitors for which dose reduction is required according to the summary of product characteristics of edoxaban.

respectively. Often, such characteristics are related to other comorbidities, and consequently also to worse prognostic characteristics. That patients in BeNe, in fact, had better prognostic characteristics than those in OEC is evidenced by three observations.

First, a history of hypertension and diabetes mellitus was less common in BeNe, resulting in slightly lower mean CHA₂DS₂-VASc (−0.4) and HAS-BLED (−0.2) scores. Second, patients were less often considered frail in BeNe than in OEC (−5.8 percentage points). Lastly, more patients had paroxysmal AF in BeNe than in OEC (+14.0 percentage points), whereas permanent AF (−10.4 percentage points) was less often reported.

Aside from the role of chance, there are two potential explanations for the differences in clinical characteristics between BeNe and OEC: (A) other prescription preferences and/or (B) other intrinsic risks between both populations.

Differences in prescription preferences

It might be that physicians in BeNe prefer to prescribe edoxaban to AF patients with better risk profiles, and, therefore, the other NOACs to patients with worse profiles, and that this trend is less observed in OEC (or perhaps not at all). For example, more patients in BeNe (3.8%) had a CHA₂DS₂-VASc of zero than in OEC (1.9%). This suggests that in our clinical practice edoxaban is more often prescribed for an upcoming or prior electrocardioversion or catheter ablation, and not for chronic stroke prevention, than in the other regions of Europe.




Figure 2. Number of dose reduction criteria.

The distribution of the number of dose reduction criteria by dose in Belgium and the Netherlands compared with in other European countries. The Y-axis and the columns illustrate the use of 60 mg edoxaban relative to that of 30 mg for each region. The percentages inside the columns show the distribution of the number of dose reduction criteria per dose of edoxaban.

Whether this notion is correct, and whether there are truly other subgroups in which physicians from BeNe relative to those from other regions of Europe prefer to initiate edoxaban over the other NOACs (or vice versa) is still unknown. Some have addressed patterns of NOAC use in BeNe, but were unable to include data for edoxaban [18–20]. Future studies that include all NOACs and address these issues are needed.




Figure 3. Annual risk scores.

The mean CHA₂DS₂-VASc and HAS-BLED scores by dose in Belgium and the Netherlands compared with in other European countries. CHA₂DS₂-VASc: congestive heart failure, hypertension, age ≥ 75 years (double weight), diabetes mellitus, stroke (double weight), vascular disease, age 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile International Normalised Ratio, elderly, drugs or alcohol.

Differences between populations

To our knowledge, no study has compared clinical characteristics of patients in either Belgium or the Netherlands prescribed one of the NOACs with those from OEC. Yet, when comparing the BeNe cohort with those used in other observational studies on NOACs, BeNe patients did not differ much with regards to age and CHA₂DS₂-VASc compared to those from Norway (mean age: 70.8–74.5 years; mean CHA₂DS₂-VASc: 2.5–2.9) [5], Scotland (mean age: 71.1–74.8 years; mean CHA₂DS₂-VASc: 2.5–3.0) [10], and the United Kingdom (mean age: 74.4–76.6 years; CHA₂DS₂-VASc: unknown) [14]. However, two studies on German and French patients with AF, showed notably higher mean CHA₂DS₂-VASc scores compared with our cohort (3.7 vs 3.5–3.9 vs 2.8, respectively) [68]. More studies on regional differences are needed to determine whether BeNe patients treated with oral anticoagulants are healthier than their peers from OEC.

Table 2. Belgium and the Netherlands: unselected versus selected patients.

Characteristics	ETNA-AF-Europe (n = 2579)	ENGAGE-AF-TIMI 48 (n = 302)
Male	1514 (58.8)	196 (64.9)
Age (years)	72.3 $\pm$ 9.1	71.5 $\pm$ 7.6
Age subgroups (years)		
<65	439 (17.0)	53 (17.5)
65–74	1056 (41.0)	102 (33.8)
≥ 75	1082 (42.0)	147 (48.7)
Body weight (kg)	82.3 $\pm$ 17.4	84.6 $\pm$ 16.5
≤ 60 kg	211 (8.9)	11 (3.6)
BMI (kg/m ²)	28.0 $\pm$ 5.1	28.8 $\pm$ 5.0
CrCl ^a (mL/min)	78.4 $\pm$ 29.7	73.4 $\pm$ 25.7
CrCl subgroups ^a (mL/min)		
<15	0 (0.0)	1 (0.3)
15–30	45 (2.0)	2 (0.7)
30–50	276 (12.5)	51 (17.1)
50–80	953 (43.0)	147 (49.3)
≥ 80	940 (42.5)	97 (32.6)
CHADS ₂ ^a	1.5 $\pm$ 1.1	2.7 $\pm$ 0.9
CHA ₂ DS ₂ -VASc ^a	2.8 $\pm$ 1.4	4.2 $\pm$ 1.3
HAS-BLED ^a	2.4 $\pm$ 1.2	1.6 $\pm$ 1.0
History of cardiovascular disease		
Hypertension	1589 (61.6)	252 (83.4)
Congestive heart failure	109 (4.2)	94 (31.1)
Myocardial infarction	130 (5.0)	40 (13.2)
Diabetes mellitus	445 (17.3)	127 (42.1)
Ischaemic stroke	154 (6.0)	49 (16.2)
Transient ischaemic attack	129 (5.0)	52 (17.2)
Atrial fibrillation type		
Paroxysmal	1668 (64.9)	117 (38.7)
Persistent	585 (22.8)	77 (25.5)
Long-standing persistent or permanent	318 (12.4)	108 (35.8)

This table summarises the clinical characteristics of patients from Belgium or the Netherlands that were enrolled in ETNA-AF-Europe and of those that were included in the ENGAGE-AF-TIMI 48 randomised trial. All values are number (%), or mean $\pm$ standard deviation.

ETNA-AF-Europe: Edoxaban Treatment in Routine Clinical Practice for Patients with non-valvular Atrial Fibrillation in Europe; ENGAGE AF-TIMI 48: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation – Thrombolysis in Myocardial Infarction 48; SD: standard deviation; BMI: Body Mass Index; CrCl: creatinine clearance; CHADS₂: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke (double weight); CHA₂DS₂-VASc: congestive heart failure, hypertension, age ≥ 75 years (double weight), diabetes mellitus, stroke (double weight), vascular disease, age 65–74 years, sex category; HAS-BLED: hypertension, abnormal renal and liver function, stroke, bleeding, labile International Normalised Ratio, elderly, drugs or alcohol.

^aSome parameters were reported by the investigators as well as recalculated based on data reported by the investigators. Presented values are those that were recalculated.

Higher stroke risks in the randomised trial than in clinical practice

Our comparisons illustrate that relative to Belgian and Dutch patients prescribed edoxaban in ETNA-AF-Europe, those from the corresponding countries in ENGAGE-AF-TIMI 48 had much higher mean CHA₂DS₂-VASc scores (+1.4), and much more often a history with any of the reported cardiovascular diseases (1.4- to 7.4-fold). Yet, our analyses also indicate that, compared with in the RCT, edoxaban is utilised in more patients with extreme characteristics in BeNe clinical practice, as demonstrated by more patients with a weight ≤ 60 kg (+5.3 percentage points), a CrCl ≤ 30 mL/min (+1.0 percentage points), and by overall higher HAS-BLED scores (mean: +0.8).

These observations are likely attributable to differences in patient selection. For example, one of the inclusion criteria for the RCT was a CHADS₂ score of ≥ 2 [3], whereas in ETNA-AF-Europe, patients were eligible for inclusion regardless of their baseline stroke risk [17].

Another important observation is that in ENGAGE-AF-TIMI 48 dose reduction criteria were strictly followed [3], whereas about a third of Belgian and Dutch patients in ETNA-AF-Europe on 30 mg edoxaban did not fulfil the criteria for dose reduction. Similar prescription patterns have been reported for the other NOACs [21], which imply that many of these off-label dose selections are not accidental, and instead, suggest that physicians are knowingly opting for the reduced dose. Although it is still unclear what the true effect is of off-label dose reductions in clinical practice, there are signs from both observational and randomised studies that such prescription reduce overall efficacy [2,3,22–24].

Thus, the ENGAGE-AF-TIMI 48 trial compared well managed warfarin with two strategies of edoxaban: 60 mg, or 30 mg in patients with at least one dose reduction criterion; and 30 mg, with a dose reduction to 15 mg. The latter strategy was not approved for clinical use as this arm was associated with 41% more ischaemic strokes than warfarin [3]. A substudy of this trial, using patients in whom edoxaban drug levels were measured ($n=6780$), showed that those on 30 mg without criteria for dose reduction experienced 43% more ischaemic strokes than those on warfarin. Conversely, 60 mg and dose reduced 30 mg (in the presence of dose reduction criteria) use were associated with a statistically nonsignificant reduction in ischaemic stroke of 6% and 4%, respectively [25]. Moreover, several descriptive studies on the use of the other NOACs in clinical practice suggest that off-label

dose reductions are associated with more thromboembolic events, without a beneficial reduction in bleeding [22–24]. These observations indicate that an important proportion of patients on edoxaban in our clinical practice in BeNe are insufficiently protected against ischaemic stroke. Still, there might be selected patients in whom off-label use of 30 mg edoxaban could be considered instead of 60 mg.

Thus, first, criteria selected for dose reduction in edoxaban were derived from patients included in pre-phase III studies [26], and might, therefore, not be generalisable to all patients in clinical practice. Second, in addition to those included in the SmPC, there are several other drugs known to increase the drug exposure of edoxaban, such as verapamil, digoxin, quinidine, and amiodarone [26–28]. Especially in patients with a CrCl and/or a body weight just above 50 mL/min and/or 60 kg, respectively, such drugs might be the tipping point from inappropriate to appropriate off-label use of the 30 mg dose. However, considering the prevalent use of off-label 30 mg edoxaban in clinical practice it is likely that many patients do not fall into this category, and are, therefore, probably insufficiently protected against ischaemic stroke.

The primary results of the ETNA-AF-Europe registry, which include ischaemic strokes and major bleeds, will answer whether the efficacy and safety of edoxaban as shown in the ENGAGE-AF-TIMI 48 trial also holds true in unselected AF-patients. With these data, we will be able to determine whether there are signs that off-label prescriptions of edoxaban are harmful.

Strengths and limitations

The main strengths of our study are that ETNA-AF-Europe is the largest prospective phase IV study on the use of edoxaban for AF in clinical practice to date, with a total of 13,639 patients from ten countries; and that patient enrolment was well distributed among the participating countries [16].

Although the latter observation strengthens the representativeness of our data, it also comes with our most important limitation since we had to arbitrarily pool data from two neighbouring countries due to modest patient numbers per country. Consequently, the regional differences presented in our study might not be completely generalisable to either Belgian or Dutch clinical practice. Even so, we doubt that this limitation has had an important effect on our results and that any differences between these regions would be clinically relevant. Thus, although mere speculation with regards to edoxaban related care, BeNe have

relatively similar patient populations with regards to overall cardiovascular risk profiles and life expectancy, as well as healthcare systems.²⁹

Conclusion

With data from the largest phase IV study on edoxaban users with AF to date, we observed several important differences regarding patient characteristics and dose selections between BeNe and OEC. This information adds to the interpretation of the international literature within BeNe routine clinical practice, and is relevant for the local implementation of dose evaluation and optimisation.

Disclosure statement

Daiichi Sankyo had the right to review the manuscript before submission. However, the authors are solely responsible for the data and their interpretation.

T.A.C. de Vries reports having received compensation for travel and accommodation expenses from Daiichi Sankyo. His primary institute (Department of Cardiology Rijnstate) has received a grant for an unrelated project from Boston Scientific. M.E.W. Hemels reports speaker fees from BMS/Pfizer, Daiichi Sankyo, Bayer, Boehringer Ingelheim, and a research grant from the Netherlands Federation of Anticoagulation clinics. F. Cools reports consultancy fees from Bayer and Daiichi Sankyo. L. Yperzeele reports speaker fees from Pfizer and Daiichi Sankyo, and consultancy honoraria from Boehringer Ingelheim and Daiichi Sankyo. A. de Veer reports consulting fees from Bayer and Boehringer Ingelheim. T. Vanassche has served as a consultant and/or has participated on advisory boards for Daiichi Sankyo, Boehringer Ingelheim, Bayer, BMS/Pfizer, Sanofi, and Leo Pharma. C. de Asmundis has received compensation from teaching purposes and proctoring from AF Solutions, Medtronic, St Jude Medical, Biotronik, and is a member of the steering committee of the ETNA-AF-Europe study. P. Kirchhof receives research support for basic, translational, and clinical research projects from the European Union (BigData@Heart; grant agreement EU IMI 116074), the British Heart Foundation (PG/17/30/32961; AA/18/2/34218), the Leducq Foundation, the Medical Research Council (UK), and the German Centre for Cardiovascular Research, from several drug and device companies active in atrial fibrillation, and has received honoraria from several such companies in the past. He is listed as inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). R. De Caterina is a co-author of the ESC Guidelines on Atrial Fibrillation 2010–2012, APPRAISE-2, ARISTOTLE, AVERROES, ENGAGE-AF-TIMI 48, and Re-DUAL PCI. He is also a steering committee member of the ETNA-AF-Europe study, and the national coordinator for Italy. He reports having received fees, honoraria and research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, BMS/Pfizer, Daiichi Sankyo, Novartis, Merck, Portola, and Roche. J.R. de Groot is supported by a personal grant from NWO ZonMW 016.146.310

and reports research grants to his institution from AtriCure, Boston Scientific, Medtronic and Abbott, and consultancy/speaker fees from AtriCure, Bayer, Daiichi Sankyo, Novartis, Medtronic, and Servier. H.J.G.M. Crijns, P. Vanacker, I. Blankoff, P. Lancellotti, G.H. Mairesse, R. Casado Arroyo, E. Catez and M. de Pauw declare that they have no competing interests."

Funding

ETNA-AF-Europe is a Daiichi Sankyo sponsored study. Daiichi Sankyo has funded the design of the ETNA-AF-Europe, the collection and analysis of data, and any editorial writing support.

ORCID

Tim A. C. de Vries  <http://orcid.org/0000-0003-1392-8193>
 Martin E. W. Hemels  <http://orcid.org/0000-0002-2373-9858>
 Frank Cools  <http://orcid.org/0000-0001-8883-5368>
 Harry J. G. M. Crijns  <http://orcid.org/0000-0003-1073-5337>
 Laetitia Yperzeele  <http://orcid.org/0000-0002-5503-5724>
 Patrizio Lancellotti  <http://orcid.org/0000-0002-0804-8194>
 Georges H. Mairesse  <http://orcid.org/0000-0002-2255-4181>
 Anne de Veer  <http://orcid.org/0000-0002-2016-5676>
 Emmanuel Catez  <http://orcid.org/0000-0002-8394-9312>
 Michel de Pauw  <http://orcid.org/0000-0001-7697-3931>
 Thomas Vanassche  <http://orcid.org/0000-0002-7404-8918>
 Carlo de Asmundis  <http://orcid.org/0000-0001-9351-0760>
 Paulus Kirchhof  <http://orcid.org/0000-0002-1881-0197>
 Raffaele De Caterina  <http://orcid.org/0000-0003-1637-574X>
 Joris R. de Groot  <http://orcid.org/0000-0002-8122-7017>

References

- [1] Beyer-Westendorf J, Camm AJ, Fox KAA, et al.; RIVER Registry Investigators. International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: rivaroxaban evaluation in real life setting (river). *Thromb J*. 2019;17:7.
- [2] Connolly SJ, Ezekowitz MD, Yusuf S, et al.; RE-LY Steering Committee and Investigators. Dabigatran vs warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361(12):1139–1151.
- [3] Giugliano RP, Ruff CT, Braunwald E, et al.; ENGAGE AF-TIMI 48 Investigators. Edoxaban vs warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013; 369(22):2093–2104.
- [4] Granger CB, Alexander JH, McMurray JJ, et al.; ARISTOTLE Committees and Investigators. Apixaban vs warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365(11):981–992.
- [5] Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral

- anticoagulants. *Eur Heart J Cardiovasc Pharmacother*. 2017;3(1):28–36.
- [6] Hohnloser SH, Basic E, Hohmann C, et al. Effectiveness and safety of non-vitamin k oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. *Thromb Haemost*. 2018;118(3):526–538.
- [7] Martinez CAA, Lanaz F, Radaideh G, et al.; XANTUS Investigators. Xantus-el: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America. *Egypt Heart J*. 2018;70(4):307–313.
- [8] Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin k antagonist oral anticoagulants: findings from the French health-care databases, 2011–2016. *BMJ Open*. 2019;9(4):e026645.
- [9] Mazurek M, Huisman MV, Rothman KJ, et al.; GLORIA-AF Investigators. Regional differences in antithrombotic treatment for atrial fibrillation: insights from the gloria-af phase ii registry. *Thromb Haemost*. 2017;117(12):2376–2388.
- [10] Mueller T, Alvarez-Madrazo S, Robertson C, et al. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. *Br J Clin Pharmacol*. 2019;85(2):422–431.
- [11] Patel MR, Mahaffey KW, Garg J, et al.; ROCKET AF Investigators. Rivaroxaban vs warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365(10):883–891.
- [12] Pottegard A, Grove EL, Hellfritzsch M. Use of direct oral anticoagulants in the first year after market entry of edoxaban: a Danish nationwide drug utilization study. *Pharmacoepidemiol Drug Saf*. 2018;27(2):174–181.
- [13] Steinberg BA, Gao H, Shrader P, et al.; ORBIT-AF Investigators. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the garfield-af, orbit-af i, and orbit-af ii registries. *Am Heart J*. 2017;194:132–140.
- [14] Vinogradova Y, Coupland C, Hill T, et al. Risks and benefits of direct oral anticoagulants vs warfarin in a real world setting: cohort study in primary care. *BMJ*. 2018;362:2505.
- [15] Lixiana: Epar – product information. European Medicines Agency; 2015 [Updated 2019 Jul 10, Accessed 2019 Aug 28]. https://www.ema.europa.eu/en/documents/product-information/lixiana-epar-product-information_en.pdf
- [16] De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (af) in Europe (ETNA-AF-Europe). *BMC Cardiovasc Disord*. 2019;19(1):165.
- [17] De Caterina R, Kelly P, Monteiro P, et al.; ETNA-AF-Europe investigators. Design and rationale of the edoxaban treatment in routine clinical practice for patients with atrial fibrillation in Europe (ETNA-AF-Europe) study. *J Cardiovasc Med (Hagerstown)*. 2019;20(2):97–104.
- [18] Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin k oral anticoagulants in the Netherlands. *Int J Clin Pharm*. 2015;37(6):1128–1135.
- [19] van den Heuvel JM, Hovels AM, Buller HR, et al. Noacs replace vka as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in the Netherlands. *Thromb J*. 2018;16:7.
- [20] Moudallel S, Steurbaut S, Cornu P, et al. Appropriateness of doac prescribing before and during hospital admission and analysis of determinants for inappropriate prescribing. *Front Pharmacol*. 2018;9:1220.
- [21] Santos J, Antonio N, Rocha M, et al. Impact of direct oral anticoagulants off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review. *Br J Clin Pharmacol*. 2020;86(3):533–547.
- [22] Arbel R, Sergienko R, Hammerman A, et al. Effectiveness and safety of off-label dose-reduced direct oral anticoagulants in atrial fibrillation. *Am J Med*. 2019;132(7):847–855.e843.
- [23] Steinberg BA, Shrader P, Pieper K, et al. Frequency and outcomes of reduced dose non-vitamin k antagonist anticoagulants: results from orbit-af ii (the outcomes registry for better informed treatment of atrial fibrillation ii). *J Am Heart Assoc*. 2018;7(4): pii: e007633.
- [24] Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin k antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. *J Am Coll Cardiol*. 2017;69(23):2779–2790.
- [25] Ruff CT, Giugliano RP, Braunwald E, et al. Association between edoxaban dose, concentration, anti-factor xa activity, and outcomes: an analysis of data from the randomised, double-blind engage af-timi 48 trial. *Lancet*. 2015;385(9984):2288–2295.
- [26] Stacy ZA, Call WB, Hartmann AP, et al. Edoxaban: a comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. *Cardiol Ther*. 2016;5(1):1–18.
- [27] Kirchhof P, Benussi S, Kotecha D, et al.; ESC Scientific Document Group. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37(38):2893–2962.
- [28] Steffel J, Verhamme P, Potpara TS, et al.; ESC Scientific Document Group. The 2018 European heart rhythm association practical guide on the use of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation. *Eur Heart J*. 2018;39(16):1330–1393.
- [29] Tjin-A-Tsoi TBPM. The Netherlands on a European scale 2019. Statistics Netherlands (CBS). 2019 [accessed 28 Feb 2020]. <https://longreads.cbs.nl/european-scale-2019/>